Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer - PR Newswire

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer    PR Newswire Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer | Eli Lilly and Company    investor.lilly.com ASCO26: Lilly details "practice changing" data for RET inhibitor in earlier stage lung cancer    FirstWord Pharma Selpercatinib Cuts Recurrence Risk in Early RET+ NSCLC    Medscape ASCO: Lilly's Retevmo aces early-stage lung cancer trial    pharmaphorum

Original source: Google News